Very Small Size Proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer

Vaccine

Volumn 30, Issue 46, 2012, Pages 6595-6599

  Aguilar, Franklin Fuentes ^a   Barranco, Jesús Junco ^a   Fuentes, Eddy Bover ^a   Aguilera, Lesvia Calzada ^a   Sáez, Yovisleydis Lopez ^a   Santana, María Dolores Castro ^a   Vázquez, Eulogio Pimentel ^a   Baker, Roberto Basulto ^a   Acosta, Osvaldo Reyes ^b   Pérez, Hilda Garay ^b   Nieto, Gerardo Guillén ^b  

^a Centro de Ingeniería Genética y Biotecnología Camagüey   (Cuba)

^b Centro de Ingeniería Genética y Biotecnología de la Habana   (Cuba)

Author keywords

Cancer vaccines; Gangliosides; GnRH; Gonadotrophin; Proteoliposomes; VSSP

Indexed keywords

GONADORELIN; GONADORELIN ANTIBODY; MONTANIDE ISA 51; PROTEOLIPOSOME; TESTOSTERONE; UNCLASSIFIED DRUG; VERY SMALL SIZE PROTEOLIPOSOME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELLULAR IMMUNITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IN VIVO STUDY; MALE; NONHUMAN; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RAT; SEROCONVERSION; TESTIS; TESTIS WEIGHT; TESTOSTERONE BLOOD LEVEL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; CANCER VACCINES; GONADOTROPIN-RELEASING HORMONE; MALE; MANNITOL; OLEIC ACIDS; PROSTATIC NEOPLASMS; PROTEOLIPIDS; RATS;

EID: 84867002732     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.020     Document Type: Article

References (19)

1. SEER cancer statistics review, 1975-2008 2011, National Cancer Institute, Bethesda, MD, [based on November 2010 SEER data submission, posted to the SEER web site]. http://seer.cancer.gov/csr/1975_2008/, N. Howlader, A.M. Noone, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, S.F. Altekruse, C.L. Kosary, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, M.P. Eisner, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin, B.K. Edwards (Eds.).
2. Simms M.S., Scholfield D.P., Jacobs E., Michaeli D., Broome P., Humphreys J.E., et al. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br J Cancer 2000, 83:443-446.
3. Garner L.L., Campbell D.T., Blake C.A. Luteinizing hormone (LH) relasing hormone; chronic effects on LH and Follicle Stimulating hormone cell and secretion in adult male rats. Endocrinology 1990, 126:992-1000.
4. Ghosh S., Jasckson D.C. Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccine. Int Immunol 1999, 11:1103-1110.
5. Jacobs E., Watson S.A., Michaeli D., Ellis I.O., Robertson J.F. Antigonadotrophin releaisng hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. Br J Cancer 1999, 80:352-359.
6. Talwar G.P., Raina K., Gupta J.C., Ray R., Wadhwa S., Ali M.M. A recombinant luteinising hormone immunogen bioeffective in causing prostatic atrophy. Vaccine 2004, 22:3713-4372.
7. Javid A., Ganaie M., Phil V., Shrivastava K. The effect of active immunization with gonadotropin releasing hormone conjugate (GnRH-BSA) ongonadosomatic indices (GSI) and sperm parameters in mice. Iranian J Reprod Med 2008, 6:119-123.
8. Bringas R, Basulto R, Reyes O, de La Fuente J. Vaccine for the reversible immunocastration of mammals. International application published under the patent cooperation treaty (PCT), Int. publ. no. WO 98/27111, 1998 June 25.
9. Nesslinger N.J., Sahota R.A., Stone B., Johnson K., Chima N., King C., et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007, 13(5):1493-1502.
10. Cirse Mesa, Joel de León, Kevin Rigley, Luis E., Fernández Very small size proteoliposomes derived from Neisseria Meningitides: an affective adjuvant for dendritic cell activation. Vaccine 2006, 24S2. S2/42-S2/43.
11. Ambrosino D.M., Bolon D., Collard H., Van Etten R., Kanchana M.V., Finberg R.W. Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophages. J Immunol 1992, 149. S2/3978-S2/3983.
12. Udono H., Srivastava P.K. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993, 178. S2/1391-S2/1396.
13. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4. S2/328-S2/332.
14. Houghten R.A., DeGraw S.T., Bray M.K., Hoffmann S.R., Frizzell N.D. Simultaneous multiple peptide synthesis: the rapid preparation of large numbers of discrete peptides for biological, immunological, and methodological studies. Biotechniques 1986, 4. S2/522-S2/526.
15. Estevez F., Carr A., Solorzano L., Valiente O., Mesa C., Barroso O. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999, 18(1-2):190-197.
16. Aucouturier J., Dupuis L., Deville S., Ascarateil S., Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002, 1:111-118.
17. Goodnow C.C., Brink R., Adams E. Breakdown of self tolerance in anergic B lymphocytes. Nature 1991, 532-536.
18. Bizzini B., y Achour A. Kinoids: the basis for anticytokine immunization and their use in HIV infection. Cell Mol Biol 1995, 41:351-356.
19. Jeannin P., Renno T., Goetsch L., Miconnet I., Aubry J.P., Deineste Y., et al. OmpA targets dendritic cells, induces their maturation and deliver antigen into the MHC class I presentation pathway. Nat Immunol 2000, 6:502-509.